Business
PharmaTher CEO Publishes Letter to Shareholders
Toronto, Ontario--(Newsfile Corp. - January 2, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher") today announced that CEO Fabio Chianelli has published a letter to shareholders.Dear Shareholders,With 2025 complete, I want to thank you for your continued support of PharmaTher. This past year marked a shift from ambitious development to concrete validation, setting the stage for what I believe will be a value-unlocking year ahead.PharmaTher's strategy is..
About this update from Pharmather Holdings Ltd
[{"type":"text","content":"Toronto, Ontario--(Newsfile Corp. - January 2, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher") today announced that CEO Fabio Chianelli has published a letter to shareholders.","length":249,"tagName":"p"},{"type":"text","content":"Dear Shareholders,","length":18,"tagName":"p"},{"type":"text","content":"With 2025 complete, I want to thank you for your continued support of PharmaTher. This past year marked a shift from ambitious development to concrete validation, setting the stage for what I believe will be a value-unlocking year ahead.","length":237,"tagName":"p"},{"type":"text","content":"PharmaTher's strategy is clear: to acquire and advance assets that can be efficiently monetized to generate product revenue, royalty income, equity value, and strategic partnerships. We currently manage two assets: our ketamine franchise and our 49% equity interest in Sairiyo Therapeutics Inc., which is focused on a novel oral formulation of cepharanthine for infectious diseases and cancer.","length":397,"tagName":"p"},{"type":"text","content":"Our strategy prioritizes non-dilutive value creation through disciplined cost control. Q4 2025 saw reduced cash burn and a lean, execution-focused organization. With the Ketamine ANDA sale closed, PharmaTher enters 2026 stronger. Our current cash, reduced expenses, and expected ANDA receipts are projected to fund our 2026 asset monetization goals without raising additional operating funds. Advancing long-term development programs, however, will require securing incremental capital via strategic partnerships or other shareholder-friendly initiatives.","length":555,"tagName":"p"},{"type":"text","content":"2025: A Year of Execution, Validation, and Strategic Positioning","length":64,"tagName":"p"},{"type":"text","content":"2025 was defined by disciplined execution across regulatory, strategic, and platform initiatives that advanced PharmaTher's evolution into an asset-focused value creation company.","length":183,"tagName":"p"},{"type":"text","content":"1) FDA approval of our Ketamine ANDA","length":36,"tagName":"p"},{"type":"text","content":"The FDA approval of our Ketamine ANDA (#217858) marked a pivotal moment for PharmaTher. This key validation not only enhances drug development and regulatory confidence but also unlocks ...